The Data on AI

Amgen AI Profile

USA Flag Thousand Oaks, CA
AI Readiness Score:   47.86

No. 113 Out Of All Companies Ranked

4 out of 21 in Healthcare and other selected competitors
Total Employees   28,000
Market Cap   $151.96 billion
CEO   Mr. Robert A. Bradway
Exchange   NASDAQ
AI AND DATA STORIES

Our estimates on data scientist numbers for Amgen trace back to several sources that we check on a monthly basis, including the company's website, career boards and other methods.

The number of data scientists a company has is important because it reflects its capability to innovate, scale AI initiatives, and leverage data-driven decision-making to maintain a competitive edge in AI development and application.

Amgen's Public AI Posture

AI Mentions in Quarterly Earnings Calls (2017-Q3 to 2022-Q3): 0.05

AI Mentions in Quarterly Earnings Calls (2022-Q4 to current): 2.44

Post ChatGPT Release, AI Mentions Moved 10.71 Standard Deviations

Posture: Reactionary

Amgen holds 4 patents focused on AI subjects. We have combed through the records of the United States Patent Office for filings related to AI for more than 500 companies. We consider a qualifying patent to be one that primarily concerns artificial intelligence or machine learning. Patents that simply mention these things do not figure in our count.

Examining CapEx shows how much Amgen invests in physical assets, highlighting its commitment to growth and the infrastructure needed to support AI initiatives.

This graph provides a comprehensive view of Amgen's strategic allocation of resources by comparing free cash flow, R&D costs, and CapEx over time, highlighting how investments in AI and innovation are balanced against financial health and infrastructure commitments. It offers insights into whether a company is sustainably prioritizing AI development amidst its broader financial strategies.